$ATOS 8-K SEC Filings

Filed On	Filing
09 Oct 2026	8-K: Entry into a Material Definitive Agreement; Material Modifications to Rights of Security Holders +1 more This STAPLED CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of October 8, 2026, is entered into by and between Atossa Therapeutics, Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a California limi...
29 Sep 2026	8-K: Other Events Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
18 Sep 2026	8-K: Regulation FD Disclosure Advancing (Z)-Endoxifen A potential best-in-class oral SERM/SERD for estrogen-driven diseases NASDAQ: ATOS www.atossatherapeutics.com Seattle, Washington Corporate & Investor Presentation September 2026 Exhibit 99.1
07 Aug 2026	8-K: Results of Operations and Financial Condition
11 Jun 2026	8-K: Entry into a Material Definitive Agreement
08 May 2026	8-K: Financial Statements and Exhibits
08 May 2026	8-K: Submission of Matters to a Vote of Security Holders
16 Apr 2026	8-K: Other Events
25 Mar 2026	8-K: Financial Statements and Exhibits
20 Feb 2026	8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
17 Feb 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
11 Feb 2026	8-K: Regulation FD Disclosure
26 Jan 2026	8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
09 Jan 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
06 Jan 2026	8-K: Other Events
04 Dec 2025	8-K: Other Events
12 Nov 2025	8-K: Results of Operations and Financial Condition
14 Oct 2025	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
26 Sep 2025	8-K: Regulation FD Disclosure
08 Sep 2025	8-K: Other Events

Comments